CrossrefInfokarte
Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up
Korean Journal of Transplantation · 2020
DOI: 10.4285/atw2020.op-1026 ↗Abstract
Kein Abstract verfügbar.
EUVIMED